We are pleased to report on a successful Digestive Disease Week (DDW) conference in San Diego. Here are the most significant highlights we would like to share with you:
- Lumendi presented two new devices – C1 and EZ1 – which we submitted to the FDA for approval a week before the conference
- Successful clinical trial for our new DPOCS device – a new device for a very attractive market
- Medical successes: Presentations on DiLumen and DiLumen C2 in the scientific program
- Successful product demonstrations and handling tests: Many potential new users expressed interest in clinically testing DiLumen
Photo above: The Lumendi team at DDW
Photos above: At test stations, doctors had the chance to experience handling DiLumen by practicing on models
MEETINGS WITH CUSTOMERS AND POTENTIAL PARTNERS
Since the company’s inception, we have accumulated over 100 DiLumen users worldwide. Half of these physicians have begun using our devices in the last 12 to 18 months. This year’s DDW was our first opportunity in three years to present Lumendi and our significantly enhanced DiLumen platform to users and industry. It was an opportunity we took full advantage of in order to showcase the breadth of our current commercial and development platform of endoluminal interventional solutions.